Hyloris' Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic IV in Eight European Markets (GlobeNewswire) - Mar 5, 2021 - "Hyloris Pharmaceuticals...today announces that its partner AFT Pharmaceuticals ('AFT') has signed an exclusive licensing agreement with Aguettant for Maxigesic IV, a novel, dual mode-of-action non-opioid pain treatment delivered through intravenous (IV) infusion...The agreement with Aguettant means that Maxigesic IV is now licensed in 20 out of the 27 EU member states (including the major pharma markets in the EU: Germany, France, Italy, and Spain) as well as the UK...AFT expects sales of Maxigesic IV in these territories to commence in early 2022...The market for post-operative pain is growing rapidly and is forecasted to reach $553 million in 2028 across the five major markets in Europe (up from $178 million in 2019)."
Licensing / partnership • Sales projection • CNS Disorders • Pain
|